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Introduction
Congenital diaphragmatic hernia (CDH) affects approximately 1 in 2500 live births [1]. The 
morbidity and mortality associated with the disease are largely due to both pulmonary 
hypoplasia and pulmonary hypertension (PH). Although overall survival has improved to 
70%, the most severe CDH patients suffer disproportionate mortality and long term 
morbidity [2, 3].
Many innovative strategies have been developed to address pulmonary hypoplasia in patients 
with severe CDH using the principles of mechanical transduction. Prenatally, fetoscopic 
tracheal occlusion has been shown to enhance lung growth by preventing egress of lung fluid 
and providing an intratracheal distending force. This approach is promising, and is being 
studied in a well-designed prospective randomized clinical trial (TOTAL trial) [4]. Postnatal 
mechanical transduction to stimulate lung growth has been performed using Perflubron-
induced lung growth (PILG) [5]. Perflubron is a perfluorocarbon liquid which has been used 
for gas exchange (partial liquid ventilation and total liquid ventilation). It is used solely as a 
distending agent in the PILG technique. The PILG technique requires ECMO support for the 
patient. The Perflubron is instilled in the endotracheal tube until a meniscus is seen, and a 
constant pressure of 8 cm of H2O is applied using a CPAP machine. Experimental studies in 
the neonatal lamb have demonstrated lung growth with alveolar proliferation using 
Perflubron as a distending agent [5]. Furthermore, experimental studies in piglets have 
demonstrated increased lung DNA synthesis after perfluorocarbon distention [6]. A pilot 
clinical study of CDH patients requiring ECMO demonstrated that one week of PILG 
improved survival [7]. Since evidence from the laboratory indicated that 3 weeks of 
distention are required to promote maximal lung growth, another prospective randomized 
clinical study was performed [5]. In this study, although PILG induced impressive lung 
growth, it did not ameliorate pulmonary hypertension and there was a higher mortality rate 
than conventional therapy [8].
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It is known that CDH patients have pathologic remodeling of the pulmonary vasculature that 
occurs during gestation and in the immediate postnatal period [9]. Pathologic remodeling of 
the pulmonary vascular tree, also known as pulmonary vascular remodeling, is a complex 
process that involves many cell types within the vascular wall, complex intercellular 
signaling, and alterations in the extracellular matrix of the pulmonary vasculature [10]. 
Extensive pulmonary vascular remodeling can lead to severe pulmonary hypertension. One 
of the key alterations that leads to the hypertensive state within the blood vessels is a change 
in the composition of the extracellular matrix that leads to an increase in collagen and 
decrease in elastin, altering the quantitative relationship between the two proteins in the 
vessel wall [11, 12]. The increase in collagen in the vessel wall alters vessel wall function by 
increasing the stiffness of the pulmonary arteries, contributing to PH [13]. Furthermore, 
there is hypertrophy and increased accumulation of smooth muscle cells in the media of 
vessel walls [14], contributing to increased cell proliferation in the vessel walls. This 
hypertrophy and accumulation leads to thickened vessel walls and decreased vessel lumens, 
further contributing to PH. Studies have also shown that there is an increased systemic 
inflammatory response in patients with CDH [15, 16], however the relationship between this 
and pulmonary vascular remodeling is still unclear. Unfortunately, therapies for the PH of 
CDH have not been developed because the mechanisms driving the pulmonary vascular 
remodeling that leads to the development of PH in CDH remain unknown. Studies have 
shown that more severe PH is associated with worse survival, but currently CDH patients are 
managed with ventilator strategies, ECMO, and pharmacologic measures that are all only 
supportive in nature [17]. Although there are other factors that play an important role in PH, 
such as vasoconstriction, in this study we focus on the histology of vessel remodeling 
because the process of vessel wall remodeling is not understood, and currently there are no 
therapies to reverse pulmonary vascular remodeling.
Although PILG stimulates lung growth in CDH patients, the effect on pulmonary vascular 
remodeling and the PH component of CDH remains unknown. We aim to determine the 
effect of PILG on pulmonary vascular remodeling in neonates with CDH requiring 
extracorporeal membrane oxygenation (ECMO)
Methods
Lung tissue samples were obtained from deceased patients enrolled in a prospective 
randomized trial of PILG in neonates with CDH at the University of Michigan [8]. There 
was a total of 16 patients in this original study that were randomized to control (conventional 
mechanical ventilation + ECMO) or treatment (PILG + ECMO) groups. A total of four 
patient tissue samples were available and all were analyzed. Three samples are from patients 
treated with PILG + ECMO, and one was treated with conventional mechanical ventilation + 
ECMO (control). All four patients eventually succumbed to PH, as documented by their 
final echocardiogram prior to death. Demographic information was collected on all patients 
and the mean value was calculated for each item in the PILG group where possible. The 
probability of survival was determined by using the CDH Study Group equation [18]. Liver 
position was also noted as a factor related to severity of clinical course in CDH.
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The lung tissue was preserved in paraformaldehyde and embedded into paraffin. Lung tissue 
was cut into 5 micrometer sections and placed on slides for histologic evaluation. Tissue was 
stained with Masson's trichrome stain in order to assess for collagen distribution in the 
vascular wall and peri-vascular space. Increased collagen deposition in the vessel wall is a 
component of pulmonary vascular remodeling. Overall collagen thickness as well as the 
presence or absence of collagen in the media and adventitia was assessed in order to evaluate 
for vascular remodeling.
Immunohistochemistry was performed with an antibody against phosphorylated Histone H3 
protein (pH3b) to assess cell proliferation in the vascular wall. Rabbit antibody for pH3b 
was used at a 1:500 dilution (Cell Signaling #9701, Danvers, MA) with a secondary goat 
anti-rabbit antibody at 1:500 dilution (Jackson #111-065-144, Westgrove, PA). 
Immunohistochemistry with antibody against macrophage antigen F4/80 was performed to 
determine macrophage levels in the vascular wall. Rat antibody for F4/80 was used at a 
1:100 dilution (AbD Serotec #MCA497, Raleigh, NC) with a secondary goat anti-rat 
antibody at 1:500 dilution (Jackson #112-065-167, Westgrove, PA).
Immunofluorescence analysis was performed to specifically evaluate the morphometry of 
the pulmonary vasculature. The slides were double stained with rabbit antibodies for CD31 
(1:100 dilution; Abcam AB28364, Cambridge, MA) and mouse antibody for alpha-smooth 
muscle actin (1:400 dilution; Dako M0851, Carpinteria, CA). Secondary antibodies were 
used for detection by immunofluorescence (1:500 dilution) with a goat anti-rabbit AF 488 
and a goat anti-mouse AF594 respectively (Invitrogen, Waltham, MA). Slides were 
visualized and images acquired with Olympus BX61 epifluorescence microscope, and the 
images were analyzed using Image-J software (National Institutes of Health). 20x images 
were used to perform total vessel counts of each sample. Vessels were counted in 15 high 
powered fields (HPF) per lung specimen. Higher power images at 40x were focused on 
vessels 20-75 um in diameter to capture arterioles. Pulmonary vasculature was identified by 
the presence of both CD31 and alpha-smooth muscle actin. For each patient, the vessel wall 
diameter (calculated as vessel wall thickness), lumen diameter, total area, and number of 
smooth muscle cell layers was calculated. Calculations were also performed to determine the 
ratio of lumen diameter to vessel wall diameter for each vessel.
Once the raw data was calculated, a mean for each sample was determined for the 
characteristics of analysis. Calculations were performed using STATA13 and Microsoft 
Excel software. Due to the fact that only one control sample was available, formal statistical 
analysis was not possible. The mean from each sample was individually compared to 
control, but significance was not determined. The data derived are descriptive in nature.
Results
Two patients were female, including the control patient, and two male. Average birthweight 
in the PILG group was 2.92 kgs. (range 2.51 to 3.15) versus 3.29 kgs. in the control. 
Estimated gestational age was 38, 38, and 39 weeks for the three PILG patients, PILG A, 
PILG B, and PILG C, respectively, and 40 weeks for the control patient. The mean days of 
life at death in the PILG group was 35 (range 23-51) vs. 135 in the control. All four patients 
Shah et al. Page 3
Pediatr Surg Int. Author manuscript; available in PMC 2016 December 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
succumbed to PH, as documented by final echocardiogram prior to death. Mean number of 
days on ECMO was 20 (range 11-28) in the PILG group vs. 18 in the control. Probability of 
survival was lower in the PILG group as all three had the liver in the chest when the control 
did not; furthermore, the calculated probability of survival based on the CDHSG equation 
was 9% and 40% in two out of three PILG patients and 67% in the control. The third PILG 
patient was born by EXIT; thus, probability could not be calculated.
To determine changes in the extracellular matrix of the pulmonary vasculature, we evaluated 
lung samples with Masson's Trichrome stain to assess collagen distribution. Histologic 
evaluation demonstrates the presence of collagen in the media and adventitia of the vessel 
wall in PILG and control samples. However, there is a larger distribution of collagen in the 
PILG patients versus control, and more specifically, accumulation of collagen in the 
adventitia of the vessel wall (Fig. 1a). When systematically measured at the level of 
arterioles (20-75 μm in diameter), collagen thickness of the vessel walls was greater in 2 of 3 
of the PILG patients compared to the control (PILG: 14.23, 35.66, and 38.46μm versus 
control: 22.16μm) (Fig. 1b).
To measure another facet of pulmonary vascular remodeling, cell proliferation was 
evaluated. PILG patients A, B and C had fewer nuclei stained with pH3b when compared to 
the control patient, with an average of 2.93, 3.13, and 2.53 nuclei per HPF versus 7.13 nuclei 
per HPF, respectively (Fig. 2). This indicates that there was lower cell proliferation present 
in the lungs of the PILG patients.
To evaluate infiltration of inflammatory cells into the pulmonary vasculature, macrophage 
invasion into the vessel wall was evaluated as a surrogate for the degree of inflammatory cell 
invasion in the lungs and pulmonary vessels. PILG had fewer macrophages per high 
powered field when compared to the control patients. (PILG: 1.2, 1.8, and 0.5 mean number 
of macrophages/HPF vs. control: 4.9 mean number of macrophages/HPF) (Fig. 3).
To better evaluate changes that occur in the pulmonary vasculature during pulmonary 
hypertension, vessel and vessel wall morphometry were evaluated. Mean vessel wall 
diameter (calculated as vessel wall thickness) was increased in all PILG patients compared 
to the control (PILG: 6.86, 10.28, and 10.35μm versus control: 4.35 μm) (Table 2). Vessel 
lumen diameter was decreased in PILG patients compared to the control patient (PILG: 
48.99, 41.75, and 36.2μm versus control: 51.56μm) (Table 2). To make sure the vessel size 
was appropriately matched across patients, total vessel area in each patient was assessed and 
they were similar (Data not shown). Lumen to vessel wall diameter ratio for each patient was 
determined. The ratio was decreased in each PILG treated patient compared to the control 
(PILG: 7.14, 4.06, and 3.49 versus control: 11.85) (Table 2). This indicates a higher degree 
of pulmonary vascular remodeling in PILG patients.
To assess for smooth muscle cell hyperplasia typically seen in pulmonary vascular 
remodeling, smooth muscle cell layers were quantitated. An increased number of smooth 
muscle cell layers was present in the PILG pulmonary vessels. (PILG: 2.47, 2.8 and 2.8 
layers vs. Control: 2.13 layers) (Table 2 and Fig. 4). Finally, the total number of vessels was 
determined in all four patient samples. There was a slight increase in the total number of 
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vessels per 20x HPF in the PILG patients when compared to the control (PILG: 4.4, 5.7, and 
4.6 vessels per HPF vs. control: 4 vessels per HPF).
Discussion
Despite advances in mechanical ventilation and ECMO, PH in CDH remains difficult to 
manage as current available therapies are merely supportive in nature. PILG has been shown 
to be an innovative strategy to promote lung growth in order to address the pulmonary 
hypoplasia component of CDH. Animal studies show a link between airway growth and 
blood vessel growth in the lung [19]; thus, it is presumed that airway growth from 
Perflubron therapy may also increase blood vessel growth and ameliorate pulmonary 
hypertension in CDH. However, despite promoting lung growth, 50% of patients died in the 
PILG arm of the clinical study due to suprasystemic pulmonary hypertension [8]. The effect 
of PILG on pulmonary vascular remodeling has previously not been studied.
In our study, it appears that PILG does not decrease the pulmonary vascular remodeling that 
leads to PH in CDH patients. The three PILG treated patients in our study had increased 
collagen thickness, increased vessel wall diameter, decreased vessel lumen, decreased lumen 
to vessel wall diameter ratio despite similar total vessel area, and increased number of 
smooth muscle cell layers when compared to the control patient treated with conventional 
mechanical ventilation + ECMO alone. This suggests a higher degree of pulmonary vascular 
remodeling in the PILG patients compared to the control. This is likely related to the fact 
that the PILG patients had a more severe form of CDH, as evidenced by all three having 
liver present up in the chest, compared to the control, who did not. Presence of “liver up” is 
known to be associated with lower survival and higher rates of ECMO use [20]. This 
coincides with the higher degree of pulmonary vascular remodeling in these three patients, 
despite the use of PILG.
Pulmonary vascular remodeling involves increased accumulation of smooth muscle cells in 
the media of vessel walls, indicated by the higher number of smooth muscle cell layers in 
the vessel wall in the PILG patients [10]. Furthermore, this increase in smooth muscle cells 
in the media results in larger vessel wall diameters and a narrowed lumen diameter, both also 
seen in the PILG patients compared to the control. The combination of effects thus results in 
a decreased lumen to vessel wall diameter ratio. Pulmonary vascular remodeling also 
involves alterations in the extracellular matrix of the pulmonary vasculature, including an 
increase in collagen [10]. We also saw evidence of this in the PILG patients, with increased 
collagen thickness in the vessel wall upon staining with Masson's Trichrome. The 
combination of remodeling in both the matrix (increased collagen) and the media (smooth 
muscle cell hyperplasia and hypertrophy) of the vessel wall leads to a non-compliant vessel 
that is fixed in an incompletely dilated state that leads to increased resistance in the 
pulmonary vasculature [21]. PILG did not ameliorate increased extracellular matrix 
production nor did it decrease smooth muscle cell proliferation in the treated patients in 
comparison to control. Despite treatment, PILG patients had a greater degree of pulmonary 
vascular remodeling and more severe pulmonary hypertension. Based upon the subjects in 
this study, PILG is not a therapy that improves pulmonary hypertension in patients with 
CDH.
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We also assessed for cell proliferation by performing immunohistochemistry with pH3b. We 
found a decreased level of cell proliferation in the PILG patients compared to the control. 
Given the increase in amount of collagen and increased accumulation of smooth muscle 
cells in the vessel walls, we anticipated a higher degree of cell proliferation in the PILG 
patients, where pulmonary vascular remodeling seemed more severe. It is unclear why the 
cell proliferation was decreased. The pH3b staining was not specific to the vasculature, and 
it is unclear as to the exact cell type that was stained. It is therefore difficult to say whether 
the cells with increased proliferation in the control patient were inflammatory cells, smooth 
muscle cells, fibroblasts, pneumocytes, or any other cell type. Furthermore, perfluorocarbons 
have been shown to decrease inflammation by suppressing the secretion of inflammatory 
cytokines and by clearing inflammatory cells from the airways; thus, the decrease in 
cellularity may be related to the anti-inflammatory properties of Perflubron [22-25]
Finally, it has been shown that CDH is associated with a systemic inflammatory response, 
with increased levels of chemokines and cytokines in the serum of patients with CDH [15, 
16]. We therefore used immunohistochemistry with antibody against F4/80 to target 
macrophages as a sign of inflammation. The PILG patients had a decreased amount of 
macrophages compared to the control patient. Again, perfluorocarbons have been shown to 
decrease inflammation, thus, it is plausible that the decreased number of macrophages 
present in the PILG group is related to the anti-inflammatory properties of Perflubron 
[22-25]. Future studies must investigate the presence of other inflammatory cell types as 
they were not assessed in this study.
Our study has several limitations. The sample size is small, included only deceased patients, 
and we had only one control for comparisons. Although all four patients have severe CDH 
based on the CDH study group equation, liver position, and need for ECMO, there still 
remains some degree of heterogeneity amongst these patients. Pulmonary vascular 
remodeling is influenced by many clinical factors; as such, standardization amongst our 4 
patients in these very important regards was not possible. Due to the limited sample size and 
inadequate number of control patients, we were unable to perform statistical analysis to 
determine if differences that were discovered are significant. Thus our study is descriptive in 
nature, but it does demonstrate findings that may stimulate questions for further study. 
Further cases for analysis are needed in the future to determine the statistical significance of 
our current findings. Another limitation to the study is that the tissue samples were labelled 
as to which study group they came from (treatment or control) and therefore the observer 
conducting the measurements of the tissue samples was not blinded to the nature of the 
samples. However, effort was made to account for this, and all calculations were made in a 
standardized fashion in order to minimize the potential for bias.
Although PILG stimulated lung growth in patients with CDH on ECMO in the clinical trial, 
all of the PILG patients who died had suprasystemic PH [8]. Though this study is only 
descriptive in nature due to the small sample size, this study demonstrates that PILG does 
not appear to have a salutary effect on the pulmonary vascular remodeling related to the PH 
of CDH. Since alveolar growth is linked to angiogenesis, the hope was that vascular 
remodeling and growth would parallel alveolar growth. We can only speculate that a longer 
duration of PILG would ameliorate PH using this strategy. Unfortunately, no specific therapy 
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exists for PH in CDH, only supportive treatment strategies. Further investigation into the 
mechanisms that lead to pulmonary vascular remodeling is needed in order to develop 
targeted treatment strategies for PH in CDH.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1a. 
Collagen thickness in arterioles as assessed by Masson's Trichrome staining. Collagen fibers 
are stained blue. Images acquired at 40x. Clockwise from top left: Control, PILG A, PILG 
B, PILG C. PILG patients have more collagen in the vessel wall, adventitia, and peri-
vascular space
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Fig. 1b. 
Collagen thickness in the vessel wall measured in micrometers. The mean of sampled 
vessels is represented by the line in the bar with the upper and lower limits of the bar 
representing the range of measurements. Vessels in PILG samples B and C have on average 
greater collagen thickness than the control
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Fig. 2a. 
Assessment of cell proliferation. Montage of images at 40x- Clockwise from the top left: 
Control, PILG A, PILG B, PILG C. Immunohistochemistry was performed with an antibody 
targeting the cell proliferation marker Phosphorylated Histone H3 (pH3b). Positive cells are 
brown. Few cells in the PILG lung tissues are pH3b positive, indicating a lack of cell 
proliferation.
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Fig. 2b. 
Assessment of cell proliferation. The bar graph is a numerical representation of the average 
number of cells positive for pH3b in each high powered field surveyed (The bar is the range 
and the mean is represented by the line). All PILG patients had lower mean cell proliferation 
than the control.
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Fig. 3. 
Assessment of inflammation. Images acquired at 40x- Clockwise from the top left: Control, 
PILG A, PILG B, PILG C. Lung tissue was stained with an antibody targeting the 
macrophage antigen F4/80. PILG patients show decreased macrophage infiltration in the 
lung compared to control. Macrophages are brown.
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Fig. 4. 
Vessel Wall Morphometry. Images acquired at 40x. Immunofluorescence was performed 
with antibodies targeting smooth muscle cells (α-smooth muscle actin-red), endothelial cells 
(CD31- green), and DNA stain (DAPI-blue). In comparison to the Control, the PILG-A 
vessel wall shows an increased number of smooth muscle cells and more prominence of the 
endothelial cells. These are indicators of a higher degree of pulmonary vascular remodeling 
in PILG treated patients
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Table 1
Characteristics of PILG and Control patients with CDH requiring ECMO
Control (n=1) PILG (n=3)
Days of Life at Death 135 35 (23-51)
Female Sex 1 1
Birth weight (kgs.) 3.29 2.92 (2.51-3.15)
Estimated Gestational Age (weeks) 40 38.33 (38-39)
Liver in chest 0 3
Length of ECMO Run (Days) 18 20 (PILG A: 11, PILG B: 21, PILG C: 28)
Day of Life of Repair (Days) 1 7.67 (2-19)
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Table 2
Characteristics of the pulmonary vasculature as determined at the level of arterioles within the lung tissue 
sections
Control A B C
Mean Wall Diameter (μm) 4.35 6.86 10.28 10.35
Mean Lumen Diameter (μm) 51.56 48.99 41.75 36.2
Ratio of Lumen to Vessel Wall Diameter 11.85 7.14 4.06 3.49
Smooth Muscle Cell Layers 2.13 2.47 2.8 2.8
Mean Number of Vessels per HPF 4.0 4.4 5.7 4.6
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